Posted today:
Dear ,
I’m pleased to attach the latest edition of Silenceworks. As you can see, April to July has been a very significant period for Benitec:
and much more. To read Silenceworks 8, please use this link. Call me if you’d care to discuss it or our programs.
- The first patient was dosed in Benitec's TT-034 Hepatitis C clinical trial
- Maxim and Shaw both initiated coverage of Benitec with ‘buy’ recommendations
- Calimmune gained approval to commence dosing the second cohort of patients in their HIV clinical trial
Regards,
Carl Stubbings| Chief Business Officer
Benitec Biopharma Limited | F6A / 1-15 Barr Street | Balmain NSW 2041 Australia
ABN: 64068943662
t: (+61 2) 9555 6986 |m: (+61) 423666374|
e:[email protected] | w: www.benitec.com |Skype: carl-stubbings
- Forums
- ASX - By Stock
- BLT
- Silenceworks latest edition
Silenceworks latest edition
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
STX
Strike hands $48.5M contract to Clarke Energy to produce 20x 4.5MW gas engines for Sth Erregulla
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares